(BRIEF) BioNTech, a leading biotechnology company, has formalized a multi-year strategic partnership with the state of Victoria in Australia, founded on an initial letter of intent identified in October 2022. The collaboration aims to strengthen the local mRNA ecosystem by reaching the Bundoora Campus of La Trobe University in Melbourne, Victoria. This facility will utilize BioNTech’s complex BioNTainer assemblies for mRNA production and aseptic filling, serving local and global partners. In addition, BioNTech will identify an mRNA Innovation Centre in Melbourne to foster mRNA-related study projects and drive their transition to clinical-stage expansion. The partnership aims to expand investigational mRNA-based medicines, specifically for the treatment of cancer, with the aim of benefiting up to 4,000 patients in Australia and New Zealand. more than a decade through clinical trials and approved remedies. BioNTech is already conducting several clinical trials in Australia and plans to expand its contributions to the region’s healthcare landscape.
(PRESS RELEASE) MAINZ, Dec. 9, 2023 /EuropaWire/ — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) announced that it has entered into a multi-year strategic partnership with the state of Victoria, Australia. , to the local mRNA ecosystem and facilitate the inventions that result from it. Based on a letter of intent agreed in October 2022, the strategic partnership aims to provide high-tech production functions and BioNTech’s expertise to organize encouraging projects for further study and development.
The State of Victoria has contracted BioNTech to develop and commission a state-of-the-art mRNA manufacturing facility tailored to the needs of the local mRNA ecosystem to strengthen local manufacturing. The site is intended to support R&D and clinical-scale manufacturing of investigational mRNA-based medicines from the local ecosystem as well as from other third parties globally.
The facility will be based on the company’s high-tech virtual production suites called BioNTainers. A unit will be supplied to manufacture the mRNA and the formulated drug. The second unit will allow for aseptic filling. BioNTainer sets are designed to offer production responses according to the wishes of the local ecosystem. The Victoria site will be at La Trobe University’s Bundoora campus in the Melbourne area. Its innovative rite is scheduled for 2024.
In addition, BioNTech will identify an mRNA Innovation Centre in Melbourne, where the company will leverage its mRNA expertise for the progression of the mRNA ecosystem in Victoria. The company will compare and identify mRNA-focused study projects from academia or the biotech industry to facilitate their transition to clinical stage progression as potential product candidates.
“BioNTech’s vision is to translate science into survival. Victoria State is one of the leading life sciences centers in the Asia-Pacific region, and we look forward to strengthening its cutting-edge studies and development,” said Professor Ugur Sahin, M. D. CEO and co-founder of BioNTech. ” It is vital that innovation does not impede in the lab, but reaches patients quickly. We are already conducting a number of clinical trials in Australia and are comparing tactics to support them. with more to come.
“The strategic partnership focuses on the empowerment of innovations in the field of mRNA by providing high-tech manufacturing capabilities and expertise to curate encouraging projects for further development,” said Sierk Poetting, Ph.D., Chief Operating Officer of BioNTech. “The BioNTainers we will be delivering are a lighthouse project tailored to the needs of the local mRNA ecosystem. The material manufactured there will support preclinical and clinical development of mRNA-based medicines.”
BioNTech intends to advance the progression of investigational mRNA-based medicines and other product applicants for the purpose of treating up to 4,000 cancer patients in Australia and New Zealand over a ten-year period, either in clinical trials or as approved treatments. it has already established a clinical trial footprint in Australia with several investigational cancer treatments for indications with significant unmet medical wishes and is lately enrolling cancer patients in Australia for five of its investigational treatments across all drug classes.
Media Contacts:
SOURCE: BioNTech
MORE ABOUT BIONTECH, ETC. :
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW DO I GET STARTED?